Corcept Therapeutics Incorporated

NasdaqCM:CORT 株式レポート

時価総額：US$10.0b

Corcept Therapeutics 将来の成長

Future 基準チェック /66

Corcept Therapeutics利益と収益がそれぞれ年間48.9%と24.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に31.5% 49.9%なると予測されています。

主要情報

48.9%

収益成長率

49.92%

EPS成長率

Pharmaceuticals 収益成長14.6%
収益成長率24.4%
将来の株主資本利益率31.46%
アナリストカバレッジ

Low

最終更新日09 Jul 2026

今後の成長に関する最新情報

Recent updates

Seeking Alpha • 14h

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

Summary Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant’s FDA approval in ovarian cancer and likely approval in Cushing’s syndrome could drive CORT revenues above $3 billion annually by decade’s end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation. Despite a forward P/S of ~10x, CORT’s $10B+ market cap is justified by multi-billion dollar peak revenue potential and expanding clinical pipeline. Read the full article on Seeking Alpha
ナラティブの更新 • Jul 09

CORT: Regulatory Uncertainty Around Key NDA Resubmission Will Drive Future Downside Risk

Corcept Therapeutics' updated analyst price target of $50, down from $95, reflects analysts incorporating lower projected revenue growth, a slightly higher discount rate, and a more conservative future P/E multiple, even as they factor in improved profit margin assumptions and recent positive relacorilant and Lifyorli milestones. Analyst Commentary Recent Street research on Corcept Therapeutics has centered on the regulatory path for relacorilant, the commercial outlook for Lifyorli in ovarian cancer, and how these factors feed into valuation assumptions.
ナラティブの更新 • Jun 25

CORT: Ovarian Cancer Launch And Cushing’s Review Will Shape Balanced Outlook

Analysts have lifted their price targets on Corcept Therapeutics to a range of $72 to $135, citing the positive relacorilant NDA resubmission, the recent Lifyorli approval, and greater clarity on the regulatory path as key reasons for the higher valuation views. Analyst Commentary Recent research on Corcept Therapeutics points to a more constructive view on the stock, with several firms lifting price targets after the relacorilant NDA resubmission and the approval of Lifyorli.
ナラティブの更新 • Jun 06

CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside

Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.
ナラティブの更新 • May 11

CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside

Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.
ナラティブの更新 • Apr 25

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback

Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.
ナラティブの更新 • Apr 11

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds

Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.
ナラティブの更新 • Mar 27

CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk

Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.
ナラティブの更新 • Mar 10

CORT: Future Generic Ruling And Oncology Data Will Drive Upside

Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.
ナラティブの更新 • Feb 24

CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside

Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.
ナラティブの更新 • Feb 09

CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside

Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.
ナラティブの更新 • Jan 26

CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside

Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.
ナラティブの更新 • Jan 10

CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside

Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.
分析記事 • Jan 01

The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%

Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...
ナラティブの更新 • Dec 17

CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks

Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.
分析記事 • Oct 07

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...

業績と収益の成長予測

NasdaqCM:CORT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20281,7538212254905
12/31/20271,4003691323025
12/31/20261,006861081504
3/31/202676947120120N/A
12/31/202576198142142N/A
9/30/2025741105163163N/A
6/30/2025716132180182N/A
3/31/2025685133177179N/A
12/31/2024675140196198N/A
9/30/2024629140142144N/A
6/30/2024570125123124N/A
3/31/2024524117125125N/A
12/31/2023482105127127N/A
9/30/202345091154155N/A
6/30/202342894135135N/A
3/31/202341494111111N/A
12/31/2022402101120120N/A
9/30/2022398117136136N/A
6/30/2022392113151151N/A
3/31/2022380112177178N/A
12/31/2021366113167168N/A
9/30/2021353106153154N/A
6/30/202134398134135N/A
3/31/202134099143144N/A
12/31/2020354106151152N/A
9/30/2020356109164165N/A
6/30/2020351114173173N/A
3/31/2020335106145146N/A
12/31/201930694N/A136N/A
9/30/201928587N/A109N/A
6/30/201926878N/A115N/A
3/31/201925876N/A105N/A
12/31/201825175N/A116N/A
9/30/2018238152N/A119N/A
6/30/2018216148N/A85N/A
3/31/2018189142N/A86N/A
12/31/2017159129N/A61N/A
9/30/201713035N/A41N/A
6/30/201710924N/A39N/A
3/31/20179313N/A25N/A
12/31/2016818N/A18N/A
9/30/2016725N/A18N/A
6/30/2016641N/A10N/A
3/31/201656-2N/A8N/A
12/31/201550-6N/A3N/A
9/30/201544-11N/A-2N/A

アナリストによる今後の成長予測

収入対貯蓄率: CORTの予測収益成長率 (年間48.9% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: CORTの収益 ( 48.9% ) はUS市場 ( 18.3% ) よりも速いペースで成長すると予測されています。

高成長収益: CORTの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: CORTの収益 ( 24.4% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。

高い収益成長: CORTの収益 ( 24.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CORTの 自己資本利益率 は、3年後には高くなると予測されています ( 31.5 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/10 06:30
終値2026/07/10 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Corcept Therapeutics Incorporated 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.